CCND1 and melanoma: Among the 62 paired samples (54/107 [50.5%] patients) with discrepancies in BRAF/cKIT/CyclinD1 mutation patterns between first and subsequent primary melanomas, majority of them (40; 64.5%) displayed differences in BRAF mutation distribution (19 with a wild-type first tumor and a mutated subsequent tumor, 19 with a mutated first tumor and a wild-type subsequent tumor, and 2 with a change in mutation variants between the two tumor lesions) (Additional file 1: Table S1).